Greenwich Lifesciences, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Greenwich LifeSciences reports 2025 financial results, highlighting progress in its Phase III Flamingo-01 clinical trial for breast cancer immunotherapy.
NASDAQ
Greenwich LifeSciences focuses on its Phase III clinical trial, Flamingo-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, while reporting a net loss of $15.8 million for 2024.
NASDAQ
Greenwich LifeSciences' annual report details progress on its Phase III breast cancer immunotherapy trial and its financial position.